Federal Contractor Misconduct Database (FCMD)
EpiPen Marketing, Sales Practices, and Antitrust Litigation
Pfizer reached a $345 million settlement with a class of consumers who alleged they overpaid for EpiPen self-injectors because of anti-competitive practices. They alleged that Mylan, which was selling EpiPens made by Pfizer, conspired to maintain the product’s monopoly through large rebates issued to insurers and Medicaid plans that refused to cover a competing medication, and by employing reverse-payment patent settlements and other tactics to thwart the emergence of generic competitors.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement